A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Authors
Valle, Juan WArmstrong, Anne C
Newman, C
Alakhov, V
Pietrzynski, G
Brewer, Julie
Campbell, S
Corrie, P
Rowinsky, E K
Ranson, Malcolm R
Affiliation
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. juan.valle@christie.nhs.ukIssue Date
2011-10
Metadata
Show full item recordAbstract
To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction (GEJ). Patients andCitation
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. 2011, 29 (5):1029-37 Invest New DrugsJournal
Investigational New DrugsDOI
10.1007/s10637-010-9399-1PubMed ID
20179989Type
ArticleLanguage
enISSN
1573-0646ae974a485f413a2113503eed53cd6c53
10.1007/s10637-010-9399-1
Scopus Count
Related articles
- Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia.
- Authors: Alakhova DY, Zhao Y, Li S, Kabanov AV
- Issue date: 2013
- Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
- Authors: Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA
- Issue date: 2007 Mar
- Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
- Authors: Bayraktar UD, Bayraktar S, Hosein P, Chen E, Koniaris LG, Rocha-Lima CM, Montero AJ
- Issue date: 2012 Sep
- Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
- Authors: Propper D, Jones K, Anthoney DA, Mansoor W, Ford D, Eatock M, Agarwal R, Inatani M, Saito T, Abe M, Evans TR
- Issue date: 2016 Oct 10
- Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer.
- Authors: Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M
- Issue date: 2004 Jun 1